

(use as many sheets as necessary)

Attorney Docket Number:	2892-406 800812-0008
-------------------------	----------------------

Sheet	1	of	2
-------	---	----	---

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231

Application Number:	10/230,133	10/695,536
Filing Date:	August 29, 2002	
First Named Inventor:	Ibert Clifton Wells	
Group Art Unit:	1621	
Examiner Name:	Not Yet Assigned	S. Kumar
Attorney Docket Number:	2892-106	800812-0008

Sheet	2	of	2
-------	---	----	---

[illegible]

Examiner Signature	S. Kumar	Date Considered	7/17/03 9/21/04
-----------------------	----------	--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for Form 1449B/PTO (Modified)
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Sheet

2

၇

2

Application Number:

Complete If Known

10230-133 10/695536

Filing Date:

AUGUST 29 2002

First Named Inventor:

Ibert Clifton Wells

Group Art Unit

1621

Examiner Name:

S. Kinner

Attorney Docket Number:

800812-0008

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS AND INFORMATION

[illegible]

**Examiner
Signature**

5.) kurier

Date _____

Considered

7/16/02

9	2104
---	------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known 10/695536	
				Application Number	09/635,286 10/730,133
				Filing Date	August 9, 2000 10/29/02
				First Named Inventor	Ibert Clifton WELLS
				Group Art Unit	1624 1621
				Examiner Name	K. Hable S. Kumar
Sheet	1	of	1	Attorney Docket Number	W16-3 (N1427-002) 2892-0008
U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.†	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
82		3,894,995		Reske et al.	07-15-1975
		4,144,244		Brace	03-13-1979
		4,331,570		Klemarczyk et al.	05-25-1982
		4,622,339		Lieb et al.	11-11-1986
		4,705,897		Alexander	11-10-1987
Examiner Signature	S. Kumar			Date Considered	7/17/03 9/21/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Unique citation designation number. ‡See attached Kinds of U.S. Patent Documents. §Enter Office that issued the document, by the two-letter code. ¶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. §Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known		10/695536
				Application Number	09/635,266 new 10/635,266 733	
				Filing Date	August 9, 2000 10/635,266 8/29/02	
				First Named Inventor	Ibert Clifton WELLS	
				Group Art Unit	1624 1621	
				Examiner Name	S. Kumar	
Sheet	1	of	1	Attorney Docket Number	W16-3 (N1427-002) 289800812-0005 2897-106	
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				To
81e		EDVINSSON, L., et al., "Reduced levels of calcitonin gene-related peptide (CGRP) but not substance P during and after treatment of severe hypertension in man," <i>J. Human Hypertension</i> , 1989, 3:267-270.				
		FAULHABER, H.D., et al., "Substance P in Human Essential Hypertension," <i>J. Cardiovasc. Pharmacol.</i> , 1987, 10(Suppl. 12):S172-S176.				
		MEYER, P., and MARCHE, P., "Cell Membrane in Hypertension," <i>The American Journal of Medical Sciences</i> , April, 1988, 295(4):396-399.				
		MORI, K., et al., "Decreases in Substance P and Vasoactive Intestinal Peptide Concentrations in Plasma of Stroke-Prone Spontaneously Hypertensive Rats," <i>Jpn. Heart J.</i> , November, 1993, 34(6):785-794.				
		RESNICK, L.M., et al., "Intracellular free magnesium in erythrocytes of essential hypertension: Relation to blood pressure and serum divalent cations," <i>Proc. Natl. Acad. Sci. USA</i> , October, 1984, 81:6511-6515.				
		SANFILIPPO, J.S., et al., "Amniotic Fluid Levels of Substance P," <i>The Journal of Reproductive Medicine</i> , August, 1992, 37(8):733-736.				
a		TAKANO, Y., et al., "Substance P immunoreactivity released from rat spinal cord after kainic acid excitation of the ventral medulla oblongata: a correlation with increases in blood pressure," <i>Brain Research</i> , 1984, 291:168-172.				
Examiner Signature	S. Kumar			Date Considered	7/17/03 9/21/04	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 09/635,266 ~~10/645,536~~
 Filing Date August 9, 2000 ~~8/29/02~~
 First Named Inventor Ibert Clifton WELLS
 Group Art Unit ~~1611~~ 162)
 Examiner Name S. Kumar
 Attorney Docket Number W16-3 (N1427-002) ~~2890-106~~

Sheet 1 of 2

U.S. PATENT DOCUMENTS

800812-0008

Examiner Initials*	Cite No.¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
816		5,268,359		Harmar et. al.	12-07-1993
		5,491,140		Bruns et al.	02-13-1996
		5,492,927		Gitter et al.	02-20-1996
		5,525,624		Gitter et al.	06-11-1996
		5,563,133		Hipskind	10-08-1996
		5,565,568		Cho et al.	10-15-1996
		5,594,022		Horwell et al.	01-14-1997
		5,607,947		Hipskind	03-04-1997
		5,610,176		Horwell et al.	03-11-1997
		5,616,562		Murphy et al.	04-01-1997
1		5,670,499		Cho et al.	09-23-1997
816		5,684,033		Cho et al.	11-04-1997
816		5,698,710		Sisto et al.	12-16-1997
Examiner Signature		S. Kumar		Date Considered	7/17/03 9/21/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB Indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 10/695-536

Application Number 09/635,266 ~~new 10/230,793~~
 Filing Date August 9, 2000 ~~10/230,793~~ 8/29/02
 First Named Inventor Ibert Clifton WELLS
 Group Art Unit 1011 162)
 Examiner Name S. Kumar

Sheet 2 of 2 Attorney Docket Number W46-3 (N1427-002) 200512-0008

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
80		FRICKEY, P.H., et al., "Preparation and Characterization of Monoclonal Antibodies to Substance P," <i>Hybridoma</i> , Nov. 6, 1991, 10:685-694.	
		HORWELL, D.C., "Use of the Chemical Structure of Peptides as the Starting Point to Design Nonpeptide Agonists and Antagonists at Peptide Receptors: Examples with Cholecystokinin and Tachykinins," <i>Bioorganic & Medicinal Chemistry</i> , 1996, 4(10):1573-1576.	
		MATTINGLY, M.T., et al. "Decreased Cell Membrane Magnesium in Some Essential Hypertension Patients," <i>Clin. and Exper. Hyper.-Theory and Practice</i> , 1991, 13:65-82 (author's reprint enclosed-total of 20 pages).	(1)
		THEODORSSON-NORHEIM, E., et al., "Neuropeptide K: A Major Tachykinin in Plasma and Tumor Tissues from Carcinoid Patients," <i>Biochemical and Biophysical Research Communications</i> , 1985, 131:77-83	
		WELLS, I.C., et al., "Abnormal magnesium metabolism in two rat models of genetic hypertension," <i>Can. J. Physiol. Pharmacol.</i> , 1992, 70:1225-1229.	

Examiner Signature S. Kumar Date Considered 7/17/03 9/2/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.